HbA1c, body mass and blood pressure are reduced as an effect induced by using canagliflozin alone or along with other diabetic medications. These are important outcomes related to the management of diabetes.
A reduction in glucose reabsorption by the proximal renal tubules and, consequently, increase of urinary glucose excretion is observed with canagliflozin (CANA) – an antihyperglycemic drug from the class known as sodium glucose co-transporter 2 inhibitors (SGLT-2Is). Guidelines from important medical associations have recommended SGLT-2Is along with metformin when the glycemic targets are not achieved. CANA has been shown to be effective by reducing not only the glycosylated hemoglobin (HbA1c) by up to 1%, but also the blood pressure and the body weight.
CANA efficacy was further evaluated in a recent study, by American researchers who analyzed its potential effects on HbA1c and other clinical endpoints such as blood pressure and body mass in an outpatient facility of people living with type 2 diabetes mellitus (T2DM). Demographic (e.g., age, sex) and laboratory (e.g., number and type of antihyperglycemic agents, glomerular filtration rate) variables were assessed in 462 T2DM individuals for two years, at two separate times. On average, the individuals were given three diabetic medications. Most of them received insulin, suggesting an advanced clinical status. HbA1C, systolic (SBP) and diastolic blood pressure (DBP), and body mass were reduced in those taking CANA. There was a direct relationship between the magnitude of change in the HbA1c level and CANA dose. However, a convenient sample, lack of randomization and variables information, follow-up measures, sample demographics, lack of control of eating habits, physical activity, and medication adherence may be important limiting factors.
CANA can be used as a significant pharmacological strategy to improve important outcomes diabetes-related complications such as HbA1c, along with body mass and blood pressure. CANA alone or prescribed with other medications was showed to be successful in the management of people living with T2DM.
Written By: Vagner Raso